Skip to content

May 5, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Regulatory
Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara

Regulatory

Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara

Pharmaceutical Business Review

Langlara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM).

Read full story

pharminent May 5, 2026 (Last updated: May 5, 2026)

Pharmaceutical Business Review

Langlara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM).

Read full story

Post navigation

Previous: ‘Seismic shift’ as obesity overtakes cancer for R&D returns

Next: UCB doubles down on TCEs with $2.2bn Candid buyout

Related Stories

Regulatory

Gene therapy’s evidence problem–lessons from recent FDA decisions

pharminent May 4, 2026

Regulatory

First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial

pharminent May 4, 2026

Regulatory

Pfizer, Arvinas join SERD club with Veppanu approval

pharminent May 4, 2026

You May Have Missed

Clinical Data

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

pharminent May 5, 2026

Commercial

Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat

pharminent May 5, 2026

Clinical Data

Cytokinetics heart drug scores in closely watched trial

pharminent May 5, 2026

Market Access

Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point

pharminent May 5, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.